Paris-based biotechnology firm Bioptimus has successfully raised $35 million in seed funding, marking a significant milestone in its mission to redefine the landscape of biological research through cutting-edge artificial intelligence (AI) technology.

The funding round was spearheaded by leading investment firms Sofinnova Partners and Bpifrance Large Venture, with notable contributions from Frst, Cathay Innovation, and tech luminary Xavier Niel, among others. This substantial investment underscores the growing enthusiasm and confidence in Bioptimus’ innovative approach to biomedicine.

Founded by a team of former Google DeepMind and Owkin scientists, Bioptimus is pioneering the development of a groundbreaking AI foundation model tailored specifically for biology. This model aims to revolutionize scientific research by integrating data across multiple scales of biological complexity, ranging from molecules to cells, tissues, and entire organisms.

CEO Jean-Philippe Vert, a prominent figure in the AI research community, emphasized the transformative potential of Bioptimus’ technology. He articulated, “The application of foundation models and generative AI to biology is set to have a profound impact in science. By harnessing the power of foundation models and advanced algorithms trained on massive amounts of biological and multimodal data across scales, we aim to capture the laws of biology that have hitherto remained too complex to be properly understood.”

Bioptimus plans to leverage its recent funding to scale up its operations and further advance its development efforts. With access to extensive datasets, including high-quality patient information sourced from academic hospitals worldwide, and utilizing state-of-the-art computing infrastructure provided by Amazon Web Services, the company is well-positioned to achieve its ambitious goals.

The significance of Bioptimus’ endeavor extends beyond traditional biomedicine. Its AI foundation model holds the promise of accelerating innovation not only in healthcare but also in environmental science and beyond. By unlocking deeper insights into biological processes and facilitating more accurate simulations, Bioptimus aims to drive scientific breakthroughs that will benefit society as a whole.

As the global landscape of AI-driven biotechnology continues to evolve rapidly, Bioptimus stands at the forefront of this revolution, poised to redefine the boundaries of what is possible in biomedical research and innovation. With the backing of seasoned investors and a world-class team of experts, Bioptimus is poised to make a lasting impact on the future of medicine.